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Background: Semen and semen-derived amyloid fibrils boost HIV infection in vitro but their impact on sexual virus
transmission in vivo is unknown. Here, we examined the effect of seminal plasma (SP) and semen-derived enhancer
of virus infection (SEVI) on vaginal virus transmission in the SIV/rhesus macaque (Macacca mulatta) model.
Results: A total of 18 non-synchronized female rhesus macaques (six per group) were exposed intra-vaginally to
increasing doses of the pathogenic SIVmac239 molecular clone in the presence or absence of SEVI and SP.
Establishment of productive virus infection was assessed by measuring plasma viral RNA loads at weekly intervals.
We found that the first infections occurred at lower viral doses in the presence of SP and SEVI compared to the
control group. Furthermore, the average peak viral loads during acute infection were about 6-fold higher after
exposure to SP- and SEVI-treated virus. Overall infection rates after a total of 27 intra-vaginal exposures to increasing
doses of SIV, however, were similar in the absence (4 of 6 animals) and presence of SP (5 of 6), or SEVI (4 of 6).
Furthermore, the infectious viral doses required for infection varied considerably and did not differ significantly
between these three groups.
Conclusions: Semen and SEVI did not have drastic effects on vaginal SIV transmission in the present experimental
setting but may facilitate spreading of virus infection after exposure to low viral doses that most closely
approximate the in vivo situation.
Keywords: Semen-mediated enhancement of viral infection, SEVI, Amyloid, SIV, Transmission, Rhesus macaqueBackground
Despite global efforts to limit the expansion of the AIDS
pandemic, HIV-1 still causes about 2.3 million new infec-
tions each year. Most of these HIV-1 transmissions result
from vaginal exposure to virus-containing semen during
sexual intercourse [1-3]. Despite this dramatic spread of
HIV-1, however, the efficiency of male-to-female intra-
vaginal transmission is surprisingly low, with only about 1
event per 200 to 10,000 coital acts [4,5]. Thus, the poor
transmissibility of HIV-1 clearly restricts the spread of the
AIDS pandemic.
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and the presence of other sexually transmitted diseases,* Correspondence: frank.kirchhoff@uni-ulm.de
1Institute of Molecular Virology, Ulm University Medical Center,
Meyerhofstrasse 1, 89081 Ulm, Germany
2Ulm Peptide Pharmaceuticals, Ulm University Medical Center,
Meyerhofstrasse 1, 89081 Ulm, Germany
Full list of author information is available at the end of the article
© 2013 Münch et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
waiver (http://creativecommons.org/publicdom
stated.factors modulating the infectiousness of HIV-1 in genital
fluids may play a key role in the efficacy of sexual trans-
mission of HIV-1 [6-8]. Multiple studies reported that
semen boosts HIV-1 infection in vitro [9-17]. This enhan-
cing effect correlates with the levels of amyloidogenic frag-
ments of prostatic acid phosphatase and semenogelins
that are abundant in human semen [12,13]. These semen-
derived peptides rapidly form amyloid fibrils that facilitate
virion attachment and may increase the infectiousness of
HIV-1 in in vitro infection assays by several orders of
magnitude [10-12]. Several agents that block this enhan-
cing activity have been reported [14-18] and related fibril-
forming peptides were developed for efficient lentiviral
gene delivery [19]. Although semen is the main vector for
the spread of HIV-1, its effect on sexual virus transmission
in vivo is currently poorly understood.
Here, we used the SIV rhesus macaque non-human
primate model [20,21] to examine possible effects of
semen and semen-derived amyloid fibrils on vaginalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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per group) were exposed intra-vaginally to increasing
doses of the pathogenic SIVmac239 molecular clone in
the presence or absence of SEVI and seminal plasma.
Productive virus infection was assessed by measuring
plasma viral RNA loads at weekly intervals.Results and discussion
To be able to use the same reagents throughout the entire
in vivo study, we first generated large quantities of SIVmac
stocks and SEVI solutions and collected pooled SP from
healthy human donors. To ensure the efficacy of these re-
agents, we next examined the effect of SEVI and SP on
the infectiousness of SIVmac and control HIV-1 stocks
in vitro. We found that SP and SEVI enhanced infection
by both HIV-1 and SIVmac, although the effects on the
latter were substantially weaker (Figure 1A and B). SP was
most effective at 10% (Figure 1A) since 50% begins to
cause cytotoxic effects [10,13]. In contrast, the enhan-
cing effect of SEVI did not saturate (Figure 1B). In limit-
ing dilution infection assays, performed as previously
reported [10], treatment with SEVI enhanced the
TCID50 of SIVmac up to 100-fold (Figure 1C), which is
about two orders of magnitude lower than previously
observed for HIV-1 [10].
Since the effects of semen and SEVI on lentiviral infec-
tion have thus far almost exclusively been examined in
human-derived cells [9-17], we next analyzed whether
they can be confirmed in primary monkey cells. To assess
possible differences in the susceptibility to SIV infection
and the enhancing effects of SEVI or SP, we utilized
PBMCs derived from all 18 animals assigned to the in vivo
vaginal challenge study. We found that SEVI increased
SIVmac239 infection of rhesus macaque PBMCs between
4.8- and 57.7-fold (Figure 2A), while SP-mediated en-
hancement ranged from 3.9- to 11.1-fold (Figure 2B). Not-
ably, the absolute levels of SIVmac infection and the
































































Figure 1 SP and SEVI enhance SIVmac less effectively than HIV-1 infe
infection of TZM-bl cells by HIV-1 NL4-3 (blue) or SIVmac239 (red). The left
only. (C) Limiting dilution analysis of SIVmac239. CEM-M7 cells were infecte
the presence of the indicated concentrations of SEVI. Indicated is the numbnot differ significantly between PBMCs derived from the
three treatment groups of animals (Figure 2C and D).
Our results showed that SEVI and SP enhance HIV-1
infection substantially more efficiently than infection by
SIVmac. Nonetheless, the impact on SIVmac infection
was readily detectable and highly significant. Thus, we
decided to proceed with the in vivo study, although the
effects in the SIV/macaque model may not fully reflect
the impact of semen and SEVI in vaginal transmission of
HIV-1. To closely mimic the situation during sexual
virus transmission we did not synchronize the menstrual
cycle of the female macaques or treat them with agents
to induce thinning of the vaginal layer. The animals were
exposed to up to 27 weekly non-traumatic vaginal chal-
lenges with gradually increasing doses of virus stocks
that were either mixed with solutions of SEVI or SP or
PBS (Figure 3). The final concentrations were 35 μg/ml
of SEVI and 90% (v/v) of SP, the former was the yield of
amyloidogenic PAP fragments from human semen [10],
while the latter approximates the 100% of semen that is
transferred during sexual intercourse. We used human
semen because the challenges required a total of ~300 ml
of this body fluid, a quantity which cannot be obtained
from macaques. Furthermore, we felt that examination of
the genuine vector of sexual transmission of HIV-1 in
humans may have higher relevance for the spread of the
AIDS pandemic than utilization of semen from a monkey
species that is not a natural host of primate lentiviruses.
However, vaginal exposure of macaques to human semen
may affect their susceptibility to SIV infection by inducing
immune reactions to the foreign antigens and local in-
flammation. Both enhancing effects due to the recruit-
ment of activated viral target cells to the sites of virus
exposure and protective effects due to the induction of
local innate immune responses are conceivable. Clearly,
the induction of immune responses to human antigens is
a potential confounding factor. Notably, however, insem-
ination is also associated with the induction of immuno-
logical processes and lymphocyte activation in humans0.8
3.3
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ction. (A, B) Effect of the indicated doses of SP (A) and SEVI (B) on
panels show infection by both viruses and the right panels SIVmac239
d in triplicate with 10-fold dilutions of the SIVmac239 virus stock in
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Figure 2 Susceptibility of PBMCs derived from macaques assigned to the in vivo study to SIVmac239 infection and to SP- or
SEVI-mediated enhancement of infection. (A, B) Effect of SEVI (A) and SP (B) on SIVmac239 infection of PBMCs derived from the 18 animals
assigned to the in vivo study. PHA/IL-2 stimulated cells were infected with SIVmac239 encoding a luciferase reporter gene [22]. Numbers above
the bars indicate n-fold infectivity enhancement observed in the presence of SP or SEVI compared to those measured in their absence. RLU/s:
relative light units per second. (C, D) PBMCs were grouped based on their belonging to the control (co), SEVI or SP groups in the subsequent
in vivo study. The box plots in C show the mean infection rates and 25th and 75th percentiles measured in the absence of SP and SEVI. The box
plots in (D) show the n-fold enhancement of SIVmac239 infection of PBMCs derived from the three groups of macaques in the presence of SEVI
(10 μg/ml) or SP (10% v/v).
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of macaques to human semen may reflect the events dur-
ing sexual transmission of HIV-1 in humans.
The susceptibility of the animals to SIVmac infection
after vaginal exposure varied considerably within each
treatment group. One macaque (15075) in the SP group
already became infected after the second exposure to
100 TCID50 (Figure 3). This animal showed signs of a
mild infection of the respiratory tract at the week after
productive SIV infection. However, there were no hints
of inflammatory bacterial or viral genital infections.
Thus, there were no obvious reasons for an enhanced
susceptibility of animal 15075 to SIV infection. In strict
contrast, five of the 18 animals (two in the control and
SEVI groups and one in the SP group) remained unin-
fected even after eight weekly exposures to 12,800
TCID50 (Figures 3 and 4A). One animal in the SEVI
group (14825) showed high levels of viremia during
acute infection but subsequently efficiently controlledvirus replication (Figure 3). Furthermore, one macaque
(14828) assigned to the group of uninfected animals
showed viral blips after the last virus exposure but did
not become systemically infected (Figure 3). On average,
the doses required for vaginal SIVmac infection did not
differ significantly between the three treatment groups
(Figures 4B and C). However, the first infections oc-
curred at lower doses in the SP (100 TCID50) and SEVI
(1,600 TCID50) groups than in the control (3,200
TCID50) group (Figures 3, 4A). Furthermore, the peak
viral loads during acute infection were on average about
6-fold higher in animals that received SEVI and SP
treated virus stocks (Figure 4D). This difference reached
significance when the SEVI/SP groups were combined
(p = 0.0243). The significance of these differences in VLs
and the underlying mechanisms remain to be deter-
mined. It is tempting to speculate that weekly exposures
to semen and seminal fibrils may enhance local infla-





















































































































































Figure 3 SIV viral RNA loads in plasma of macaques after vaginal exposure to SIVmac239 in the absence (control) or presence of SEVI
or SP. The vertical gray line indicates the time point of the last virus inoculation. The detection limit was 40 viral RNA copies per ml plasma.
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http://www.retrovirology.com/content/10/1/148activated viral target cells may facilitate initial virus
spread. It has also been reported, however, that seminal
fluid has immunosuppressive activity [28]. Thus, reduced
innate immune control provides an alternative explan-
ation for higher peak VLs after treatment with seminal
plasma.
Our finding that semen may promote virus infection
and spread after exposure to very low viral doses is in
agreement with the results of two earlier studies that
also reported increased vaginal SIV infection of ma-
caques in the presence of semen, but only under condi-
tions of low viral inoculums [29,30]. Finally, we foundthat polymorphisms in TRIM5α reported to affect the
susceptibility to SIV infection [31] had no significant im-
pact on the acquisition of SIVmac in the present study
(Additional file 1: Figure S1). This is in agreement with
the previous finding that the macaque adapted SIV-
mac239 strain is resistant against both wild-type and
variant TRIM-5α alleles [31].
Due to the limited number of animals and their high
variability in susceptibility to vaginal SIV infection, our
study provides only very preliminary insights into the
role of semen and SEVI in sexual transmission of HIV-1.












































































































Figure 4 Infection of rhesus macaques after vaginal exposure to SP- and SEVI-treated SIVmac. (A) Proportion of infected animals in the
three treatment groups as a function of the number of weekly vaginal exposures. (B) Administered viral dose (TCID50) leading to systemic
infection and (C) total viral dose (cumulative TCID50) received by the animals until they became systemically infected. Two of the six macaques in
the control and SEVI groups and one animal in the SP group are not shown since they remained uninfected after final virus exposure. (D) Peak
viral loads during acute infection in the control, SEVI and SP groups.
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prise since attachment factors that increase the sticki-
ness of viral particles may only promote intra-vaginal
virus transmission in the presence of micro-lesions in
the vaginal mucosal layer and at low viral doses (sche-
matically outlined in Figure 5). In agreement with the
findings of previous studies [29,30], our results suggest
that semen may increase the risk of vaginal transmission
after exposure to low viral loads. Notably, even the re-
peated low dose challenge model utilizes viral quantities
that are substantially higher than those transferred in
humans because they usually achieve virus infection
after about 10 to 20 challenges, whereas about 200 to
10,000 exposures are required for vaginal virus transmis-
sion by sexual intercourse. Furthermore, the effects of
SEVI and SP on SIV infection in vitro were substantially
weaker than those observed on HIV-1. Thus, the results
of the present study may underestimate the effect ofsemen on the efficiency of HIV-1 transmission by sexual
intercourse.
Conclusions
In summary, our results show that SP and SEVI did not
have drastic effects on vaginal SIV transmission in the
present experimental settings, using non-synchronized
macaques and increasing viral doses. However, SP and
SEVI may facilitate spreading of virus infection after ex-
posure to low viral doses that most closely approximate
the in vivo situation. This study provides hints for the
design of future animal studies of the effects of semen
on the efficacy of sexual transmission of HIV-1. The ef-
fects of SP and SEVI on SIVmac239 infection in vitro
were relatively weak compared to those previously ob-
served for HIV-1. Notably, SIVmac239 was adapted to
macaques through intravenous injections [32]. Thus, this



































Figure 5 Schematic outline of the possible roles of viral dose and the presence of microlesions in the effect of seminal attachment
factors on sexual transmission of SIV and HIV-1. Viral particles are indicated as black dots, mucus as pink line and the multi-layered vaginal
epithelium by dashed lines. Infection of viral target T cells is indicated by the “+” symbol. Please note that this simplified model needs to be
challenged in experimental studies.
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Currently, we are examining whether chimeric viral con-
structs (SHIVs) containing the HIV-1 Env glycoprotein
may better reflect the full magnitude of the enhancing
effects of semen and SEVI observed on HIV-1 infection.
Furthermore, it is known that the phase of the menstrual
cycle and different levels of vaginal inflammation, affect
the susceptibility to HIV-1 and SIV infection [29,33,34].
Thus, consideration of the levels of pre-existing genital
inflammation and/or rectal instead of vaginal exposure
may deliver significant results with a reasonable number
of animals. It would also circumvent biases due to men-
strual cycle asynchrony, while the higher susceptibility
associated with the presence of a single columnar layer
of the rectal epithelium would reduce variations between
donors. Such studies seem highly warranted since a bet-
ter understanding of the role of semen and semen-




Semen samples were collected at the “Kinderwunschzentrum”
Ulm (Germany) from healthy individuals with informed
consent. Pooled semen was generated from samples de-
rived from > 20 individual donors. All ejaculates were
allowed to liquefy for 30 min. SP represents the cell free
supernatant of semen pelleted for 5 min at 10.000 rpm.
In all experiments, aliquots were rapidly thawed and an-
alyzed immediately.
Generation of SEVI
PAP248-286 was produced by standard Fmoc solid-phase
peptide synthesis, purified by preparative RP HPLC and
analyzed by HPLC and MS. Lyophilized synthetic peptides
Münch et al. Retrovirology 2013, 10:148 Page 7 of 9
http://www.retrovirology.com/content/10/1/148were suspended in serum-free DMEM at concentrations
of 5 to 10 mg/ml. Fibril formation was induced by over-
night agitation at 37 °C and 1400 rpm using an Eppendorf
Thermomixer and verified by Congo Red staining or elec-
tron microscopy.
Virus stocks and infectivity
Virus stocks of HIV-1 NL4-3 and SIVmac239 were gen-
erated by transient transfection of 293 T cells as de-
scribed [10].
Effect of SP and SEVI on virus infection in vitro
The effect of SP and SEVI on HIV-1 and SIVmac infection
and limiting dilution infection analyses were performed
using adherent TZM-bl reporter cells or CEM-M7 cells as
described previously [10,13].
Animals
The animals assigned to this study were mature female
rhesus monkeys (Macaca mulatta) of Chinese origin.
These rhesus macaques were housed at the German Pri-
mate Center in accordance with the German Animal
Welfare Act and in compliance with the European
Union guidelines on the use of nonhuman primates for
biomedical research. The study was approved by an ethics
committee authorized by the Lower Saxony State Office
for Consumer Protection and Food Safety.
Vaginal exposure
To examine possible effects of SP and SEVI on SIV
transmission, rhesus macaques were exposed vaginally
once a week for up to 28 weeks to the SIVmac239 mo-
lecular clone except for a gap between week 20 and 22.
The viral application procedure had been described be-
fore [35]. The intra-vaginal viral exposures were per-
formed using escalating doses, i.e. with 25 TCID50 for
the first four applications, 100 TCID50 for the following
four challenges, and 400 TCID50 for another four expo-
sures. Thereafter, doses were doubled after every second
week eventually reaching 12.800 TCID50 for the final
eight inoculations (see also Figure 3). Challenges were
stopped 1 week after viral RNA became detectable in
plasma with levels >100 copy equivalents/ml, indicating
systemic infection. To prepare the inocula, virus stocks
were diluted to a concentration 10-fold above the de-
sired dose and either diluted in PBS buffer only (control
group), a SEVI dilution to achieve a final concentration
of 35 μg/ml (SEVI group) or undiluted SP (90% v/v; SP
group). Virus exposures were done by non-traumatic in-
oculation of 0.25 ml of untreated, SP- or SEVI-treated
virus into the vaginal tract. All experiments were done
under highly controlled conditions by the same personnel
using the same virus stock and inoculum preparation
procedure.Viral RNA loads
Viral RNA copies were quantified in purified SIV RNA
from plasma using TaqMan-based real-time PCR on an
ABI-Prism 7500 sequence detection system (Applied
Biosystems) as described [36].Detection of TRIM5 polymorphisms
RNA was isolated from PBMCs using Qiagen RNAeasy
Plus Minikit. RNA was reverse transcribed using Quanti-
tect Reverse Transcription Kit (Qiagen, Germany). Trim5α-
sequences were amplified by PCR using primers Trim5-for
5′-AGTGGAGAAGCTGCTATGGCT −3′and Trim5-rev
5′-ATGGACAAGAGGTGCTGTACAC −3′. Amplified
PCR fragments were cloned into pJET1.2 (CloneJET PCR
cloning kit, Fermentas). DNA-sequences of up to 5 clones
in homozygous macaques were determined using Big Dye
Cycle Sequencing. Amplicons were analyzed on an ABI
3130xL Genetic Analyser (Applied Biosystems). Sequence
comparison was done with the freely available program
Bioedit. TRIMcyp detection was performed by analysis
of PCR fragment length polymorphism essentially as de-
scribed [31].Data analysis
The PRISM package version 5.0 (Abacus Concepts, Berkeley,
CA) was used for all statistical calculations.Additional file
Additional file 1: Figure S1. Susceptibility of rhesus macaques differing
in their TRIM5 gene to infection by SIVmac239 after vaginal exposure.
Animals that became infected after vaginal virus exposure were grouped
based on the presence of homozygosity for TRIM5TFP allele (Wt, n = 5 of
7) or TRIM5ΔΔQ (Del, n = 3 of 4) or heterozygous (Het, n = 4 of 6).
TRIMCypA was absent in the macaques. Given are the numbers of
animals that became infected out of the total number of macaques with
the respective TRIM5 genotype. For one infected macaque the genotype
could not be unambiguously determined. (A) Viral dose (TCID50) at the
week before the animals became systemically infected. (B) Total viral
dose (cumulative TCID50) inoculated into the animals until they became
infected.Abbreviations
HIV-1: Human immunodeficiency virus type-1; AIDS: Acquired
immunodeficiency syndrome; SEVI: Semen derived enhancer of viral
infection; SIVmac: Simian immunodeficiency virus of rhesus macaques;
SP: Seminal plasma; PBS: Phosphate buffered saline; TCID50: Median tissue
culture infective dose; RP-HPLC: Reversed-phase high-performance liquid
chromatography; MS: Mass Spectrometry.
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